Company intelligence / Profile preview

Modus Medica

Sweden

Ownership: Private
Development stage: Other

Overview

Modus Therapeutics is in Phase II clinical trials with its lead compound sevuparin, a heparinoid developed for sepsis, severe inflammation, sickle cell anemia, and chronic kidney disease with anemia. Sevuparin has shown a favorable safety profile and is distinguished by its low anticoagulant activity, enabling higher dosing than standard heparinoids. The ongoing Phase II study in chronic kidney disease with anemia is supported by recent funding and expected to complete by the end of 2026.

Therapeutic areas: HematologyImmunologyInfectious DiseasesNephrology
Modalities: Small moleculePolysaccharideHeparinoid
Industry: Biotech

Beyond the preview

Go deeper on Modus Medica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modus Medica.

Explore the full profile